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Abstract 
Background: Early life is a period of drastic epigenetic remodeling in which the epigenome is especially sensitive to 
extrinsic and intrinsic influence. However, the epigenome‑wide dynamics of the DNA methylation changes that occur 
during this period have not been sufficiently characterized in longitudinal studies.
Methods: To this end, we studied the DNA methylation status of more than 750,000 CpG sites using Illumina Methyl‑
ationEPIC arrays on 33 paired blood samples from 11 subjects at birth and at 5 and 10 years of age, then characterized 
the chromatin context associated with these loci by integrating our data with histone, chromatin‑state and enhancer‑
element external datasets, and, finally, validated our results through bisulfite pyrosequencing in two independent 
longitudinal cohorts of 18 additional subjects.
Results: We found abundant DNA methylation changes (110,726 CpG sites) during the first lustrum of life, while far 
fewer alterations were observed in the subsequent 5 years (460 CpG sites). However, our analysis revealed persistent 
DNA methylation changes at 240 CpG sites, indicating that there are genomic locations of considerable epigenetic 
change beyond immediate birth. The chromatin context of hypermethylation changes was associated with repressive 
genomic locations and genes with developmental and cell signaling functions, while hypomethylation changes were 
linked to enhancer regions and genes with immunological and mRNA and protein metabolism functions. Signifi‑
cantly, our results show that genes that suffer simultaneous hyper‑ and hypomethylation are functionally distinct from 
exclusively hyper‑ or hypomethylated genes, and that enhancer‑associated methylation is different in hyper‑ and 
hypomethylation scenarios, with hypomethylation being more associated to epigenetic changes at blood tissue‑
specific enhancer elements.
Conclusions: These data show that epigenetic remodeling is dramatically reduced after the first 5 years of life. 
However, there are certain loci which continue to manifest DNA methylation changes, pointing towards a possible 
functionality beyond early development. Furthermore, our results deepen the understanding of the genomic context 
associated to hyper‑ or hypomethylation alterations during time, suggesting that hypomethylation of blood tissue‑
specific enhancer elements could be of importance in the establishment of functional states in blood tissue during 
early‑life.
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Background
Epigenetic modifications such as DNA methylation are 
known to influence gene expression and thus biological 
function [1] and alterations in epigenetic marks are found 
in processes ranging from physiological development and 
cellular differentiation [2] to pathological scenarios, as 
well as aging [3, 4]. Reflecting the developmental changes 
of the individual, most epigenetic changes occur dur-
ing embryogenesis, where waves of extensive epigenetic 
reprogramming take place [5]. After birth, epigenetic 
modification continues to take place throughout the 
human lifespan, both at the DNA methylation and chro-
matin levels [6] and precise DNA methylation markers of 
age have recently been developed [7].
It seems, however, that the first years of life constitute 
the post-natal period with the most substantial epige-
netic changes [8, 9] and, moreover, prenatal and early 
life epigenetic aggression has been linked to countless 
health-related consequences in a wide variety of settings 
[10]. Thus, the characterization of childhood DNA meth-
ylation changes could help uncover genomic locations of 
functional relevance.
While age-related changes have been functionally 
linked to many biological processes, other alterations 
are known to arise in a stochastic fashion [11, 12]. As 
such, the use of longitudinal experimental designs can 
allow for the identification of DNA methylation altera-
tions in a more controlled environment [9, 13–16], and 
this approach has also been employed to study the influ-
ence of clinical parameters on the epigenome, especially 
during early childhood [17]. However, longitudinal DNA 
methylation studies which analyze data from more than 
two time points remain scarce [17–19] and most of the 
previous literature stands on now surpassed methyla-
tion screening technologies such as the Infinium Human 
Methylation 450K BeadChip which mainly interrogates 
CpG-dense genomic regions, even though the functional 
association between DNA methylation and gene expres-
sion is increasingly being described for CpG-sparse loca-
tions such as enhancers and gene bodies [20].
This study, therefore, presents, to the best of our 
knowledge, the first 3-point longitudinal genome-wide 
DNA methylation analysis of blood tissue employing the 
Illumina Infinium MethylationEPIC BeadChip, which 
allowed us to characterize two distinct phases of early-
life epigenetic changes during the first 10 years of life at 
the same time as focusing on various types of genomic 
regions, using a clinically well-characterized cohort. Fur-
thermore, we integrated our generated data with exter-
nal chromatin and enhancer datasets in order to obtain 
a functional view of the observed age-related DNA 
methylation changes. Finally, we applied bisulfite pyrose-
quencing in order to technically and biologically validate 




Newborn children born at term (gestational age 
≥ 37  weeks) after uncomplicated pregnancies and in 
the absence of perinatal illness in the General Hospital, 
University of Valencia, Spain, were randomly selected 
to enroll in the study. The characteristics of each gesta-
tion and delivery were obtained from routine obstetrical 
records, and the gestational age at birth was measured 
using the method of Ballard et  al. [21]. Groups were 
established on the basis of birth weight: < 10th percen-
tile for their sex (SGA); between 10th and 90th percentile 
(AGA); and > 90th percentile (LGA) [22]. The subjects 
were followed-up at 5 and 10 years of age.
Anthropometric parameters and biochemical analyses
At both 5 and 10 years, height was measured to the near-
est 0.5  cm using a standardized wall-mounted height 
board, and body weight to the nearest 0.1  kg using a 
standard beam balance scale with the barefoot subjects 
wearing light clothing. Body mass index (BMI) was cal-
culated as the weight in kilograms divided by the square 
of the height in meters (see Table 1 and Additional file 1: 
Table S9 for this and other clinical information).
Sample collection, DNA extraction, and quantification
Blood samples were collected from a total of 29 subjects 
at different testing times (n = 51). Cord blood samples 
were taken at birth and peripheral venous blood sam-
ples were taken from each child during their fifth and 
tenth year of life. Genomic DNA was extracted with the 
RealPure kit (RealPure, REAL, Durviz) and quantified 
with the Nanodrop-2000C Spectrophotometer. A DNA 
quality check was performed with Quant-iT PicoGreen 
dsDNA reagent.
Genome‑wide DNA methylation analysis
Microarray-based DNA methylation profiling was per-
formed with the Illumina Infinium MethylationEPIC 
BeadChip on 33 paired blood samples from 11 subjects 
collected at birth, 5 and 10 years of age. Bisulfite conver-
sion of DNA was performed using the EZ DNA meth-
ylation kit (Zymo Research) following the manufacturer’s 
recommendations, but with the modifications described 
in the Infinium assay methylation protocol guide. Pro-
cessed DNA samples were then hybridized to the Bead-
Chip following the Illumina Infinium HD methylation 
protocol at the Centro Nacional de Genotipado (CEGEN-
ISCIII, Spain, http://www.cegen .org).
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DNA pyrosequencing
The DNA methylation status of representative CpG sites 
(cg07547765, cg11047325, cg03830443) was evaluated 
by bisulfite pyrosequencing using the primers described 
in Additional file 2: Table S8. Technical validations were 
performed for all 11 subject samples at the three time 
points (n = 33) and biological validations were performed 
on two independent cohorts: (1) peripheral blood from 
9 children at birth and 5  years of age (n = 18), and (2) 
peripheral blood from 9 different children at 5 and 
10  years (n = 18). Genomic DNA was isolated follow-
ing standard phenol–chloroform extraction protocols. 
Bisulfite conversion of isolated DNA was performed 
in accordance with the EZ DNA methylation-gold kit 
Table 1 Clinical characteristics of the 11 subjects enrolled in the study
FF formula feeding, BF breast feeding, VD vaginal delivery, CS cesarean section, AGA appropriate for gestational age, SGA small for gestational age, LGA large for 
gestational age, HDL high-density lipoprotein, LDL low-density lipoprotein
Subject
At 0 years








1 Male VD FF 40 35.0 3580 AGA 51.0
2 Male CS FF 40 34.0 3800 AGA 50.0
3 Male VD FF 38 31.0 2155 SGA 46.0
4 Male VD FF 37 32.5 2720 AGA 47.0
5 Female VD BF 37 33.0 2540 AGA 47.0
6 Female VD BF 38 32.0 2400 AGA 48.5
7 Male CS FF 41 35.0 3550 AGA 52.5
8 Female CS FF 38 34.5 3540 AGA 49.5
9 Female VD BF 39 33.0 3940 LGA 51.0
10 Male VD FF 39 35.0 3860 LGA 50.0
11 Female CS BF 39 31.0 2340 SGA 45.5
Subject
At 5 years
Creatinine Insulin HDL LDL Triglycerides Weight (g) Body mass 
index
Height (cm)
1 0.3 1.8 47 101 60 18,700 14.6 113.0
2 0.4 2.0 60 123 93 22,700 21.4 103.0
3 0.6 2.9 52 118 55 17,000 13.8 111.0
4 0.3 5.8 61 120 69 15,700 14.9 102.5
5 0.3 4.7 58 103 79 22,500 16.7 116.0
6 0.3 2.7 56 109 56 16,600 14.4 107.5
7 0.3 2.1 44 109 45 16,800 14.1 109.0
8 0.4 7.0 59 98 69 26,100 18.6 118.5
9 0.3 4.5 47 118 81 22,000 15.2 120.5
10 0.4 4.2 83 128 58 22,500 17.0 115.0
11 0.4 7.6 54 66 34 23,100 14.6 113.0
Subject
At 10 years
Creatinine Insulin HDL LDL Triglycerides Weight (g) Body mass 
index
Height (cm)
1 0.5 3.3 47 110 52 27,300 15.6 132.5
2 0.5 3.7 53 117 69 37,600 22.9 128.0
3 0.6 5.2 59 122 46 31,500 14.6 147.0
4 0.5 10.9 64 134 59 34,100 17.2 141.0
5 0.5 12.5 55 147 77 42,900 21.3 142.0
6 0.4 9.1 48 97 66 30,000 15.8 138.0
7 0.4 7.1 40 92 64 27,800 16.5 129.8
8 0.5 9.7 61 111 52 46,000 21.5 146.2
9 0.4 3.2 47 88 88 30,100 17.7 130.5
10 0.6 4.5 99 107 41 38,200 18.3 144.5
11 0.6 6.3 52 65 33 37,000 17.6 145.0
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(Zymo Research) following the manufacturer’s instruc-
tions. After PCR amplification, pyrosequencing was per-
formed using PyroMark Q24 reagents and a vacuum prep 
workstation, equipment and software (Qiagen).
MethylationEPIC BeadChip data preprocessing
All analyses were carried out using the statistical soft-
ware R (version 3.4.2). IDAT files from the methylatio-
nEPIC BeadChip were preprocessed following a pipeline 
based on the R/Bioconductor package minfi (version 
1.22.1) [23]. Probes where at least one sample had a 
detection p-value > 0.01, probes located in chromosomes 
X and Y, probes overlapping genetic variants [24] and 
crossreactive and multimapping probes [25] were dis-
carded for downstream analyses. β-values were normal-
ized using the Noob method [26] implemented in minfi, 
followed by a BMIQ normalization [27] implemented in 
the R/Bioconductor package ChAMP (version 2.8.9) [28]. 
M-values were calculated from the normalized β-values 
through a logit transformation (R/Bioconductor package 
lumi, version 2.28.0) [29] and employed for downstream 
analyses. Multidimensional scaling (MDS) and princi-
pal component regression analyses were used to identify 
potential confounding variables (R/Bioconductor pack-
ages Enmix, version 1.12.4) [30]. When specified, blood 
cell-type composition was calculated by the Houseman 
method [31]. However, to correct for batch effects and 
unwanted sources of variation in the data we performed a 
surrogate variable analysis [32] with the R/Bioconductor 
package sva (version 3.23.4) [33] because this procedure 
seeks to adjust for any confounders, including cell-type 
heterogeneity [34]. The number of latent factors was esti-
mated using the “leek” method, but it is of note that no 
surrogate variables were found after the normalization 
procedures for our generated datasets.
Differential DNA methylation analyses
Differentially methylated probes (dmCpGs) were calcu-
lated with the R/Bioconductor package limma (version 
3.32.10) [35]. A linear model was fitted between meth-
ylation levels as response variable, the variable of interest 
(age group), the aforementioned surrogate variables and 
the information of the paired samples (patient group) for 
each of the analyses: 0 vs. 5 and 5 vs. 10 years old. The 
set of p-values obtained from the tests was adjusted for 
multiple comparisons using the Benjamini–Hochberg 
method to control for false discovery rate (FDR < 0.05). 
An additional threshold of shift size was applied, filtering 
out significant probes with M-value changes of less than 
0.5, as has been suggested elsewhere [36]. Venn diagram 
representations of the relationships between statisti-
cally significant dmCpGs were generated with the online 
resource provided by the UGent/VIB bioinformatics unit 
(available at http://bioin forma tics.psb.ugent .be/webto 
ols/Venn/). Further enrichment analyses were performed 
by means of two-sided Fisher’s tests (p < 0.05 significance 
threshold), measuring effect size either by odds ratio 
(OR), or by the difference between observed counts and 
expected hypergeometric means, employing appropriate 
backgrounds for the interrogated probes in each given 
context.
Density of CpG analysis
For each of the probes in the methylation arrays, density 
of CpG was measured as the number of genomic CpGs 
present divided by the number of those possible in a 
2 kbp window centered on the CpG location under study. 
Wilcoxon non-parametric tests were used to determine 
whether there were significant differences between the 
density distributions of the CpGs belonging to each sub-
set of interest and the densities of the array probes in the 
background. A significance level of 0.05 was employed 
for all tests. Shift size was measured using median differ-
ences and Cliff ’s Delta (CD).
CGI status and genomic region analysis
CGI (CpG island) membership was assigned to each 
probe using the Illumina EPIC annotation with the R/
Bioconductor package and IlluminaHumanMethyla-
tionEPICanno.ilm10b2.hg19 (version 0.6.0). Genomic 
region position was assigned using the R/Bioconductor 
packages TxDb.Hsapiens.UCSC.hg19.knownGene (ver-
sion 3.2.2) and ChIPseeker (version 1.12.1) [37]. Statisti-
cal significance with respect to concrete CGI status or 
genomic region was determined by two-sided Fisher’s 
tests (significance level p < 0.05), and ORs were used as a 
measure of the association effect with respect to a par-
ticular feature. Appropriate backgrounds which included 
all the probes interrogated by the EPIC array in each of 
the comparisons were used for statistical purposes.
Region set enrichment analysis
Enrichment analyses were performed with the R/Bio-
conductor package LOLA (version 1.6.0) [38], which 
looks for over-enrichment by conducting one-sided 
Fisher’s tests (p-value < 0.05 significance threshold), by 
comparing overlap of probes (10  bp probe-centered 
windows) with the dataset of interest. Enrichment of 
histone marks was determined using histone ChIP-
seq peak tracks (H3K4me1, H3K4me3, H3K27me3, 
H3K36me3, H3K9me3 and H3K27ac marks) from 98 
epigenomes (primary tissues, cultures and cell lines) 
obtained from the NIH Roadmap and ENCODE pro-
jects [39, 40] and integrated into the LOLA extended 
software (datasets obtained from http://datab io.org/
regio ndb). The same method was employed for 
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chromatin-segment analysis using the expanded NIH 
Roadmap ChromHMM 18-state model tracks for the 
same 98 epigenomes, generated from the previous 
histone marks (custom database generated with data 
obtained from http://egg2.wustl .edu/roadm ap/). In 
a similar fashion, enhancer enrichment analysis was 
performed using the enhancer tracks defined in the 
EnhancerAtlas database [41] (custom database gen-
erated with data obtained from http://enhan cerat las.
org/downl oad.php) for 65 genomes (primary tissues, 
cultures and cell lines) defined by the consensus com-
bination of different independent experimental data-
sets such as histone marks, DNAse hypersensitive sites 
(DHS) and transcription factor binding sites (TFBS). 
This last dataset was also used to create the CpG-gene 
network shown in Fig.  4c: CpGs were first mapped 
to enhancers in at least one of the 22 EnhancerAtlas 
tracks corresponding to blood tissue and cell type, and 
afterwards plotted using the R/CRAN package igraph, 
where network nodes represent CpG sites or genes, 
while network edges reflect interactions between the 
enhancer element containing the CpG and the corre-
sponding associated gene.
Gene ontology analyses
Gene ontology enrichments were calculated using the R/
Bioconductor package missMethyl (version 1.10.0 gometh 
function) [42], which performs one-sided hypergeomet-
ric tests taking into account and correcting for any bias 
derived from the use of differing numbers of probes per 
gene interrogated by the array. The annotation data-
base that was interrogated is contained within the R/
Bioconductor package GO.db (version 3.4.1). Appropri-
ate backgrounds of total probes for each given context 
were employed in the corresponding analyses. Addition-
ally, because a great number of genes contained both 
hyper- and hypomethylated probes, certain gene ontol-
ogy enrichments were performed only on those genes 
that were exclusively hyper- or hypomethylated. Further 
analyses were also performed by grouping the annotated 
CpGs into gene regions, using the annotations provided 
in Additional file 3: Table S1 (column “annotation”): “pro-
moter” is formed by collapsing “Distal promoter” and 
“Promoter (≤ 1 kb)”, “gene body” is formed by collapsing 
“3′ UTR”, “5′ UTR”, “Intron”, “Exon” and “Downstream”). 
epigenomes Additional file  4: Table  S6 contains the full 
information on the gene ontology analyses. To help 
with the visualization of the results, the ontologies were 
graphically summarized using the online tool REViGO 
(available at http://revig o.irb.hr/) [43], which performs 
semantic similarity analyses in order to reduce the num-
ber of redundant functional terms obtained.
Results
Genome‑wide profiling of DNA methylation changes 
during the first 10 years of life
To characterize DNA methylation changes that occur 
during the first years of life, we analyzed the methyla-
tion status of 783,659 CpG sites in cord, 5-year-old and 
10-year-old paired blood samples from 11 subjects (see 
Table 1 and Fig. 1a) using the Illumina Infinium Meth-
ylationEPIC BeadChip. After preprocessing our data 
(see “Methods”), we applied an empirical Bayes mod-
erated t test to identify CpGs differentially methylated 
between the different age groups (dmCpGs; FDR < 0.05) 
(see “Methods”). We found 110,726 CpGs whose meth-
ylation level significantly changed from birth to 5 years 
(0 → 5), but only 460 from 5 to 10 years (5 → 10). The 
0 → 5 widespread methylation changes consisted of, 
respectively, 59,749 and 50,977 CpGs hyper- or hypo-
methylated over time, while 130 and 330 CpGs, respec-
tively, were found to be hyper- or hypomethylated 
over the 5 → 10 years period (Fig. 1b, Additional file 3: 
Table  S1). Notably, hypomethylation changes were 
found to be more pronounced than hypermethylation 
changes between 0 and 5 years, while the magnitude of 
change was more balanced in both directions between 
5 and 10 years (Additional file 5: Figure S1).
Next, we determined the genomic distribution of the 
dmCpGs identified, distinguishing between CpG island-
related regions and gene-related regions (Fig.  1c). As 
compared to the distribution of the array background, 
hypermethylated CpGs were found to be enriched at 
CpG islands for both 0 → 5 and 5 → 10 changes (Fish-
er’s test; both p < 0.001, odds ratios (ORs) = 1.2 and 7.4, 
respectively) and impoverished at open sea locations 
(Fisher’s test; both p < 0.001, ORs = 0.6 and 0.2 respec-
tively), while the inverse was the case for hypomethyl-
ated CpGs, that is they were very enriched at open sea 
regions (Fisher’s test; both p < 0.001, ORs = 2.4 and 6.9, 
for 0 → 5 and 5 → 10, respectively) and very impov-
erished at CpG islands (Fisher’s test; both p < 0.001, 
ORs = 0.1 and 0.03 for 0 → 5 and 5 → 10, respectively). 
As regards gene-related locations, hypermethylated 
CpGs were enriched at promoters and distal promot-
ers (Fisher’s test; both p < 0.001, ORs = 1.04 and 1.5 for 
0 → 5 and both p < 0.001, ORs = 2.2 and 1.4 for 5 → 10) 
and impoverished at intronic regions for 0 → 5 changes 
(Fisher’s test; p < 0.001, OR = 0.8) and at both intronic 
and intergenic regions for 5 → 10 changes (Fisher’s 
test; both p < 0.001, ORs = 0.4 and 0.4), while in con-
trast, hypomethylated CpGs were preferentially found 
at intronic and intergenic regions for both age bands, 
(Fisher’s test; p < 0.001, ORs = 1.6 and 1.3, in these 
regions respectively, for 0 → 5 and p < 0.01 and < 0.001, 
ORs = 1.4 and 2.7, respectively, for 5 → 10).
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Lastly, we analyzed the genomic density of the dmCpGs 
found (see “Methods”), which confirmed that hypermeth-
ylation occurred at genomic regions dense in CpG dinu-
cleotides, while hypomethylation appeared at CpG-poor 
regions (Fig. 1d, Wilcoxon test; all p < 0.001, median dif-
ferences (MD) and Cliff ’s deltas (CD) compared to array 
background 0.014/0.15 and − 0.014/− 0.29 for 0 → 5 and 
0.05/0.5 and − 0.02/− 0.5 for 5 → 10 hyper- and hypo-
methylated CpGs, respectively).
On the whole, these analyses reveal strong differences 
between DNA methylation changes that occur dur-
ing the first years of life, where extensive methylation 
changes are observed between 0 and 5 years, while only 
moderate changes occur between 5 and 10  years. Strik-
ingly, while the genomic distribution of these changes 
appeared to be similar, we found that the changes occur-
ring in the first lustrum of life were of a greater magni-
tude that those occurring in the second lustrum (Fig. 2a, 
Wilcoxon test; p < 0.001, MD = 0.02, CD = 0.2). Moreo-
ver, these differences, which were predicted by the PCA 
analysis (Fig. 1a), did not seem to be related to any major 
changes in the composition of blood cell types, as shown 
by the hierarchical clustering analysis of their predicted 
cell types (see “Methods” and Additional file 6: Table S2), 
where the samples did not show extensive age-associated 
clustering (Fig. 2b).
Chromatin and functional context of early‑years DNA 
methylation changes
In order to study the functional context in which the 
DNA methylation changes identified occurred, we inte-
grated our results with previously published data from 
NIH Roadmap Epigenomics and ENCODE relating to 
ChIP-seq experiments describing the genome-wide 
localization of the histone modifications H3K4me1, 
H3K4me3, H3K27ac, H3K36me3, H3K27me3 and 
H3K9me3 across different blood cell types and cell lines 
(see “Methods”). Due to the low number of probes, 
most of the enrichment analyses were unsuccessful for 
5 → 10 changes (results available in the Additional file 7: 
Table  S3, Additional file  8: Table  S4, Additional file  9: 
Table S5).
By using this approach, we found that CpGs that were 
hypermethylated during the first 5  years of life were 
strongly associated with the repressive histone modifica-
tion H3K27me3, while hypomethylated CpGs were asso-
ciated with the active histone modification H3K4me1 
(Fig. 3a, see Additional file 7: Table S3 for the full data).
a b c
d
Fig. 1 DNA methylation changes during the first years of life. a Principal Component Analysis (PCA) for 783659 CpG sites across all samples in our 
study. The two PCs represented explain approximately 30% of the variance in methylation levels. b Stacked barplots indicating the total number 
of dmCpGs detected as either 0 → 5 or 5 → 10 changes (see Additional file 3: Table S1 for the detailed names and annotations of the dmCpGs). 
c Stacked barplots depicting the relative distribution of dmCpGs and of the array background according to their CpG island‑related or gene 
location‑related status. d Violin plots showing the distribution of genomic CpG density for the detected dmCpGs and array background
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Subsequently we analyzed the enrichment of these 
dmCpGs for 18 chromatin states, as defined in a Hidden 
Markov Model (HMM) built from the previous histone 
modifications (see “Methods”). The results evidenced 
that hypermethylation occurred at enhancer states 
associated with bivalent chromatin (i.e. formed by the 
simultaneous presence of repressive and active marks) 
and polycomb repressive domains, while hypometh-
ylation occurred at states associated with enhancers, 
especially of the intragenic type (Fig.  3b, see Addi-
tional file 8: Table S4 for the full data). To gain a deeper 
understanding of enhancer-associated methylation 
changes, we integrated our data with the EnhancerAtlas 
database of predicted enhancers across 65 tissues (see 
“Methods”). This approach enabled us to character-
ize hypermethylated CpGs as being weakly associated 
with enhancers present in tissue and embryonic tissue 
whereas hypomethylated CpGs appeared more strongly 
associated with enhancers across all datasets, but 
particularly those specifically related to blood tissue 
(blood cell lines and primary cells) (Fig.  3c, see Addi-
tional file 9: Table S5 for the full data). Taken together, 
these results highlight the different functionality of the 
regions where DNA methylation is gained or lost dur-
ing the first 5 years of life and suggest that hypometh-
ylation could be more relevant than hypermethylation 
in the establishment of epigenetic patterns at enhancers 
controlling tissue-specific functions.
Lastly, we performed gene ontology analyses on the 
genes containing the dmCpGs. In order to avoid bias due 
to genes with both hyper- and hypomethylated dmCpGs, 
we conducted the analyses on those genes that were 
either exclusively hypermethylated or exclusively hypo-
methylated, also controlling for differences in the number 
of CpGs analyzed for each gene in the array (see “Meth-
ods”). This led to the finding that hypermethylated genes 
were mainly linked to developmental and cell-to-cell 
signaling processes, albeit with other notable ontologies 
also involved, such as response to retinoic acid. Hypo-
methylated genes, on the other hand, were enriched in 
metabolic terms related to mRNA and protein metabo-
lism, immune response and mitosis (Fig.  3d, see Addi-
tional file 4: Table S6 for the full data). Curiously, when 
looking at the ontologies of dmCpGs belonging to genes 
that experienced both hyper- and hypomethylation, the 
main roles of the genes affected were with respect to 
cell surface signaling and intracellular component trans-
port (Additional file  10: Figure S2A, Additional file  4: 
Table  S6). This suggests that genes undergoing both 
hyper- and hypomethylation may well have different cel-
lular functions than those that are differentially methyl-
ated in one direction only. This prompted us to examine 
the ontologies for all of the hyper- or hypomethylated 
a
b
Fig. 2 DNA methylation changes and composition of cell types. a Violin plots indicating the distribution of absolute changes in β‑value for 0 → 5 
and 5 → 10 dmCpGs. b Heatmap depicting the different predicted proportions of blood cell‑types for the different samples, which are clustered by 
unsupervised hierarchical clustering
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probes (i.e. without taking into account the fact that 
they might be associated with genes that also contained 
probes with change in the opposite direction), which 
were also different (Additional file 10: Figure S2B, Addi-
tional file 4: Table S6): while the 0 → 5 hypermethylation 
ontologies did not substantially change, the hypometh-
ylation terms appeared related more to cellular function, 
localization and activation, and membrane function, with 
immune terms being were maintained (Additional file 10: 
Figure S2, Additional file 4: Table S6). This last observa-
tion implies that not taking into account the existence 
of simultaneously hyper- and hypomethylated genes 
could alter the results obtained by ontology-enrichment 
analyses.
Taking into account these last findings, we extended 
our analyses to characterize gene ontologies depending 
on the gene region of the associated dmCpGs. We divided 
the 0 → 5 dmCpGs into promoter-, exon-, intron- or gene 
body-associated, hyper- or hypomethylated dmCpGs (8 
groups in total), in order to identify differences, for exam-
ple, between the ontologies of genes that suffered DNA 
methylation changes in their promoters versus genes 
with changes in their gene bodies. The results (Addi-
tional file 11: Figure S3, Additional file 4: Table S6), when 
compared to those previously found without segregat-
ing dmCpGs by context (shown in Fig. 3d) showed that 
genes associated to different functions suffered changes 
at different locations. For hypermethylated CpGs (Addi-
tional file 11: Figure S3A), the main functions related to 
development and signaling seen in Fig. 3d were found on 
genes with promoter- and exon-associated DNA meth-
ylation gains, while the functions associated to genes 
containing exon- or gene body-(the majority of which is 
exons) methylation increases were considerably differ-
ent, manifesting functions such as GTPase signaling, ion 
transport or cell projection. For hypomethylated CpGs 
(Additional file  11: Figure S3B), the initially observed 
functions related to mRNA metabolism, protein trans-
port or immune response were also found in genes with 
promoter-associated DNA methylation loses (which 
were, though, much more enriched in immunologi-
cal functions), while, again, the functions observed for 
genes containing exon- or gene body-associated meth-
ylation reduction changed, being more related to signal 
transduction and movement of subcellular components. 
On the whole, these observations reinforce the idea that 
DNA methylation changes occur at different gene regions 
depending on the functionality of the affected gene.
Persistent DNA methylation changes during the first 
10 years of life
After conducting the analyses of DNA methylation, we 
made use of the longitudinal design of our study to com-
pare the changes occurring in the 0 → 5 compared to 
the 5 → 10 period. Interestingly, we discovered an over-
enriched subset of 240 dmCpGs that were altered in the 
first 5 years of life which continued to change in the fol-
lowing 5 years [Fig. 4a, Fisher’s test; p < 0.001, OR = 6.6, 
expected hypergeometric mean (EHM) = 65]. No sig-
nificant gene ontologies were found for this set after 
correcting for multiple comparisons, although the top 
hypermethylation terms were related to developmental 
processes, and those for hypomethylation with metabolic 
and immunological activities (data not shown).
We subsequently filtered out CpGs with changes of less 
than 10% in β-value in order to retain those with more 
plausible biological roles, leaving 36 CpGs (Table  2). 
These remaining CpGs manifested two kinds of behav-
ior: either strong first-lustrum changes with weaker sec-
ond-lustrum changes, or a trend of constant (moderate) 
change (Fig. 4b, see Additional file 12: Figure S4 for all 36 
CpG plots). A total of 16 different genes related to these 
select 0 → 5→10 dmCpGs, and, notably, two of the 36 
CpGs were mapped to the HOXB7 gene. Since a propor-
tion of these CpG sites were not associated with any gene 
and many of them were located in open sea regions (see 
Table 2), we made use of the EnhancerAtlas database to 
map them to enhancer elements in the 22 different types 
of blood tissue and cells shown in Fig.  3c (see “Meth-
ods”), and constructed a network with the linked to the 
Fig. 3 Chromatin and functional context of DNA methylation changes. a Heatmaps depicting significant (p < 0.05) enrichment of hyper‑ and 
hypomethylated 0 → 5 dmCpG sites with different histone marks, in a selection of 21 different blood tissue and cell types (see Additional file 7: 
Table S3 for 98 full cell and tissue types, and also 5 → 10 dmCpG enrichments). The color code indicates the significant enrichment based on the 
odds ratio (OR). b Heatmaps displaying significant (p < 0.05) enrichment of hyper‑ and hypomethylated 0 → 5 dmCpG sites with different chromatin 
states, in a selection of 21 different blood tissue and cell types (see Additional file 8: Table S4 for 98 full cell and tissue types, and also 5 → 10 dmCpG 
enrichments). The color code indicates the significant enrichment based on the OR. c Heatmaps showing significant (p < 0.05) enrichment of 
hyper‑ and hypomethylated 0 → 5 dmCpG sites with predicted enhancers in 65 different cell and tissue types (see Additional file 9: Table S5 for 
full data, and also 5 → 10 dmCpG enrichments). The color code indicates the significant enrichment based on the OR. d Treemap plots indicating 
the results of REViGO semantic analyses of significantly enriched (FDR < 0.05) gene ontology biological process terms for genes containing 0 → 5 
dmCpGs. In total, 402 and 345 significant terms were found for hyper‑ and hypomethylated dmCpGs, respectively (see Additional file 4: Table S6 for 
full results, including molecular function and cellular component terms, and also 5 → 10 dmCpG enrichments)
(See figure on next page.)
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enhancer elements containing the dmCpGs (Fig.  4c). In 
this way we thereby revealed additional relationships 
with other genes, with some sites, such as cg07061387, 
showing relationships with up to 3 different genes. 
Taken together these results indicate that the majority of 




Fig. 4 Comparison of 0 → 5 and 5 → 10 DNA methylation changes. a Venn diagrams illustrating the overlap between 0 → 5 and 5 → 10 dmCpGs 
(the results of a Fisher’s test for over‑enrichment of the overlap is shown). b Plots illustrating the age‑dependent change in β‑value for 4 examples 
of dmCpGs common to both 0 → 5 and 5 → 10 (see Additional file 12: Figure S4 for all 36 CpG plots). c Network of gene–enhancer interactions 
observed between dmCpGs mapped to enhancer elements in blood tissue and cell types and associated genes. The number of connections 
between nodes reflects the mapping of a dmCpG to enhancers in more than one track
Table 2 CpG sites that change substantially during the first 10 years of life
Name Location UCSC RefGene Name Location UCSC RefGene Name Location UCSC RefGene
cg13949829 Island MIR1225;PKD1 cg12024906 Island HKR1 cg07690222 Open Sea TMTC2
cg01323777 Island KCNAB3 cg23201812 Open Sea cg05498680 Open Sea
cg00002033 Island LRFN1 cg01654035 Open Sea cg11047325 Island SOCS3
cg23669081 Island HOXB7 cg03853945 Open Sea cg01331772 Open Sea
cg17238334 Open Sea LOC102477328 cg18311495 Open Sea cg16022195 S‑Shore
cg01511232 Island cg26617011 Open Sea cg03465600 Open Sea PARD3B
cg01577707 Open Sea MIR100HG cg03830443 S‑Shore ZFPM2 cg22398226 N‑Shore
cg07547765 Island HOXB7 cg24199558 Open Sea cg02920129 Open Sea ZNF385D
cg07061387 Open Sea CD200R1 cg12628061 Open Sea cg13254363 Open Sea
cg24348981 Open Sea cg13420364 Open Sea cg05346619 Open Sea
cg13329407 Open Sea cg18647570 Open Sea DHX8 cg10097598 Open Sea
cg19567415 Open Sea TANC2 cg19509778 Island FOXI2 cg19076536 Open Sea
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continuation of those that occur during the first 5 years 
of life, although there also appear to be certain CpG sites 
that show a more linear, and constant, trend of change 
along the first 10 years of life.
Finally, we performed both technical and experimental 
bisulfite pyrosequencing validations of three of the CpGs 
found at the HOXB7 (cg07547765), SOCS3 (cg11047325) 
and ZFPM2 (cg03830443) genes (Fig.  5, see Additional 
file  13: Table  S7 for full data). Firstly, we analyzed the 
methylation value of the 11 subjects at three time points 
(n = 33), which demonstrated a very strong correlation 
between the Infinium MethylationEPIC BeadChip and 
pyrosequencing technology (Fig.  5a, b, Pearson correla-
tion coefficient = 0.91, p < 0.001). Secondly, we evaluated 
the methylation status of the same CpGs in the periph-
eral blood of an independent longitudinal cohort of 9 
children measured at birth and 5  years of age (n = 18), 
along with another independent longitudinal cohort of 
9 different children measured at 5 and 10  years of age 
(n = 18) (Fig.  5c, see Additional file  1: Table  S9 for the 
clinical information relating to these cohorts). This bio-
logical validation showed that the DNA methylation 
a c
b
Fig. 5 Technical and experimental validations. a Scatter plot showing the correlation between DNA methylation measurements performed by the 
Infinium MethylationEPIC BeadChip and by bisulfite pyrosequencing for 3 CpGs across the 11 subjects at the 3 time points (red, linear correlation 
estimation; grey, 1:1 line). b Box plots depicting the DNA methylation values of 3 CpGs measured by the Infinium MethylationEPIC BeadChip 
(top) and by bisulfite pyrosequencing (bottom). c Box plots indicating the DNA methylation values of the same 3 CpGs measured by bisulfite 
pyrosequencing in two independent cohorts, each comprising 9 children: measured (1) at 0 and 5 years of age and (2) at 5 and 10 years of age
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alterations identified can be reproduced in independent 
cohorts, thus underscoring the significance and robust-
ness of the methylation changes found in this study.
Discussion
In the present study we examined the genome-wide 
methylation profile of 33 longitudinal blood samples from 
11 children at 0 (newborn), 5 and 10 years of age. Firstly, 
we found that extensive DNA methylation changes occur 
during the first 5 years of life, while much less epigenetic 
remodeling takes place in the following 5 years. As many 
as 110,726 CpG sites were found to have altered DNA 
methylation values when comparing newborn and 5 year-
old samples, with a slight tendency toward an increase in 
methylation with age (54% of dmCpGs), while only 460 
CpGs exhibited significant methylation changes between 
5 and 10  years of age, 72% of which lost methylation. 
These findings are in line with the current literature 
which describes early-years epigenetic changes as being 
the most important of the postnatal period [8]. What is 
more, our three time point study design allowed us to 
directly compare the alterations occurring during two 
different early-years intervals, demonstrating that after 
5 years, epigenetic reshaping is dramatically reduced. In 
the same vein, Acevedo and colleagues in their reporting 
of longitudinal DNA methylation changes during the first 
5  years of life noted that in the third year these already 
seem to be weakening [19]. Aside from being more 
numerous, we found DNA methylation changes to be far 
more pronounced in the first lustrum of life than the sub-
sequent one, which may have importance in terms of the 
functional influence of these methylation alterations on 
gene expression. Moreover, this observation did not seem 
to be related to considerable changes in cell-type com-
position occurring in the first 5 years as compared to the 
following 5.
We next examined the genomic distribution of the 
dmCpGs found, which revealed that hyper- and hypo-
methylation changes occur at very different locations: 
loss of methylation being observed at CpG-poor regions 
such as open sea locations, including intronic and inter-
genic regions, for both 0 → 5 and 5 → 10 changes, while 
methylation gain occurred at CpG-denser regions like 
CpG islands and gene promoters for both of the age 
intervals examined (although 0 → 5 changes were more 
similar to array distribution). These findings, with excep-
tions [19] are in line with most studies describing age-
related DNA methylation changes, both in the early years 
[8, 16] and later years of aging [44, 45]. The fact that the 
great majority of hypomethylation changes were found 
at open sea regions underscores the value of screening 
technologies that examine CpG-sparse regions to accu-
rately characterize DNA hypomethylation scenarios.
After identifying the genomic distribution of the age-
related methylation changes, we sought to characterize 
the functional contexts associated with these loci. To 
achieve this, we integrated our DNA methylation data 
with external datasets describing histone modifications, 
chromatin states and enhancers for different tissue and 
cell types. These analyses primarily considered 0 → 5 
dmCpGs because of the low number of 5 → 10 dmCpGs 
detected, which hindered the enrichments. The results 
evidenced a link between DNA hypermethylation and 
the repressive histone mark H3K27me3, and with chro-
matin states related to polycomb repressive domains and 
bivalent chromatin enhancers, while DNA hypometh-
ylation occurred mainly at H3K4me1 regions and intra-
genic enhancers, as has been previously shown [46, 47]. 
Furthermore, when mapping the methylation changes to 
an enhancer library of 65 different tissues, we found that 
hypermethylation displayed a much lower overall enrich-
ment at enhancer sites than hypomethylation, and while 
the former occurred mainly at enhancers in normal and 
embryonic tissue, the latter was particularly enriched in 
tissues and cell types related to blood. These observations 
suggest differences in the functionality of the enhancer-
associated methylation changes that occur during the 
first 5 years of life depending on whether there is a gain 
or loss of methylation. Moreover, as studies are increas-
ingly describing enhancer-associated DNA methylation 
as the main expression-correlated methylation phenom-
enon [20, 48, 49], our results point towards the enhancer-
enriched DNA hypomethylation observed perhaps being 
of more importance in the control of gene expression 
than DNA hypermethylation. Indeed, enhancer meth-
ylation is in general negatively correlated to their activ-
ity [50], and thus it would make sense that the epigenetic 
changes that occur during the final stages of development 
are accompanied by the inactivation of general develop-
mental enhancer elements, while tissue-specific (blood) 
enhancers become activated. In this setting, our data sug-
gest that the early-life DNA methylation loss enriched 
at tissue-specific enhancer regions observed in our data 
could reflect the establishment of epigenetic active pat-
terns defining tissue function during this period of life, 
while enhancers associated to development are already 
epigenetically repressed and suffer less important (hyper-
methylation) changes.
Another approach to studying the functional impor-
tance of DNA methylation changes is through the map-
ping of dmCpG sites to genes and then analyzing the 
related ontologies. Given that DNA methylation is irreg-
ularly distributed throughout the different parts of a gene 
[1], and because a great proportion of our mapped genes 
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contained both hyper- and hypomethylated dmCpGs, 
we only performed the ontology analyses, firstly, on 
genes that exclusively either gained or lost methylation. 
We found that 0 → 5 DNA hypermethylation changes 
were principally related to developmental functions 
and cell-to-cell signaling, while hypomethylation was 
primarily linked to mRNA and protein metabolism, 
immune response and mitosis. It is worth mentioning 
that hypermethylation was also associated with terms 
such as growth, reproduction and response to retinoic 
acid, a molecule involved in organogenesis [51] as well 
as hematopoiesis [52]. Significantly, when we consid-
ered the ontologies of genes containing both hyper- and 
hypomethylated probes, we found considerable differ-
ences, implying that these genes could play different 
functional roles to those that are exclusively hyper- or 
hypomethylated. Moreover, when we examined the 
ontologies without making these distinctions, we found 
that, while hypermethylation ontologies did not con-
siderably change, hypomethylation terms shifted from 
mRNA and protein metabolism to cellular localization 
and activation or GTPase activity (maintaining immuno-
logical terms). These latter findings are more in line with 
those reported in previous works which did not describe 
separating exclusively hyper- and hypomethylated genes 
[8, 14, 16, 19]. However, the fact that we found a change 
in function suggests that not taking into consideration 
the presence of concurrently hyper- and hypomethyl-
ated genes could affect the conclusions drawn from gene 
ontology analyses. On the whole, these results suggest 
that it is not only differentially hyper- or hypomethylated 
enhancers that have differing roles, but also differentially 
hyper- or hypomethylated genes, with the former being 
more related to general developmental functions, and the 
latter being involved in, among other things, immuno-
logical functions, thus reflecting the functionality differ-
ences observed for enhancer elements. In a final analysis, 
we further segregated the 0 → 5 dmCpGs into groups 
depending on their gene location (promoter, gene body, 
intron, exon) and also found changes between the gene 
ontologies of genes containing promoter- or exon-asso-
ciated dmCpGs versus intronic- or gene body-associated 
dmCpGs, both for hyper- and hypomethylated CpGs. 
These observations imply that different genes, associated 
to different functions, suffer DNA methylation changes 
in different regions, which could help explain why DNA 
methylation changes in different contexts can have differ-
ent consequences, and also suggests that the response of 
the gene elements to epigenetic changes during early life 
is gene region-specific.
Finally, we compared the DNA methylation changes 
that occur during the first two lustra of life, finding 
that the majority of the 5 → 10 changes are in fact a 
continuation of the 0 → 5 changes. By looking at the 
dmCpGs with the most substantial change in both age 
groups we defined 36 CpG sites with consistent DNA 
methylation changes during the first 10  years of life. 
These locations followed one of two trends: (1) strong 
0 → 5 changes followed by weak 5 → 10 changes or (2) 
moderate overall 0 → 5→10 changes. Many of these 
CpGs were located at genes with important functions, 
such as development-associated HOXB7 [53], which con-
tained 2 CpGs, and the GATA-interacting ZFPM2 [54]. 
Interestingly, although both these genes are related to 
developmental functions, the first was found to be hyper-
methylated while the second was hypomethylated, and, 
what is more, the dmCpG associated with ZFPM2 was 
also mapped to an enhancer element (Fig.  4c). Another 
zinc finger-family gene which we found to be altered, 
ZNF385D, has been associated to language impairment 
and reading disability in children [55]. Although this 
observation could be related to its function during prena-
tal brain development, the fact that the gene-associated 
dmCpG (cg02920129) shows a similar trend of methyla-
tion gain during both the 0 → 5 and 5 → 10 periods of life 
(Additional file  12: Figure S4) points towards a possible 
functional relevance throughout early life. It would thus 
be of interest to further study the link between the meth-
ylation status of ZNF385D and language impairment or 
reading disability. The CD200R1 gene, which encodes for 
a myeloid- and T-cell distinctive transmembrane recep-
tor [56] was found to be linked to an hypomethylated 
dmCpG (cg07061387), which was subsequently found 
to be associated with enhancer elements related to up 
to 3 different genes (ATG3, NEPRO, GCSAM) when the 
0 → 5 → 10 dmCpGs were mapped to enhancers in dif-
ferent blood tissues, indicating that at least some of the 
DNA methylation changes found could exert an influence 
on genes other than the those on which the dmCpGs are 
located.
Lastly, we performed technical and biological valida-
tions of the methylation status of 3 dmCpGs located 
on the HOXB7, the SOCS3 and the ZFPM2 gene using 
bisulfite pyrosequencing. As expected, we observed a 
high correlation between the results of the Infinium 
MethylationEPIC BeadChip analysis and the pyrose-
quencing, albeit the DNA methylation values detected 
by the array were slightly higher, a fact which has been 
noted before [57]. Subsequently we examined the meth-
ylation of these CpGs in two independent longitudinal 
cohorts spanning the first and second lustra of life, and 
found that the DNA methylation changes found in the 
previous experiments were robust and reproducible in 
independent subjects.
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Conclusions
Collectively our results show that major epigenetic 
remodeling takes place during the first 5  years of life. 
However, despite a dramatic reduction, some genomic 
loci continue to experience considerable DNA meth-
ylation changes during the second lustrum of life. This 
observation illustrates that there are CpG sites whose 
change in methylation status could have functional roles 
beyond early postnatal development. In addition, we 
show that genes that experience simultaneous hyper- and 
hypomethylation are functionally distinct from those 
that are exclusively hyper- or hypomethylated. Finally, we 
have found that enhancer-associated methylation is dif-
ferent in the hyper- and hypomethylation scenario, the 
latter being more relevant and related to blood-specific 
enhancer elements, while developmental enhancer ele-
ments could already be epigenetically defined at birth, 
suffering changes of lesser importance during early life.
Additional files
Additional file 1: Table S9. Clinical characteristics of the 18 subjects from 
the independent cohorts.
Additional file 2: Table S8. Primer sequences for bisulfite sequencing of 
the validated CpGs.
Additional file 3: Table S1. Lists of annotated 0→5 and 5→10 dmCpGs.
Additional file 4: Table S6. Gene ontology enrichment analysis of 0→5 
and 5→10 dmCpGs. Enrichments were calculated from the difference 
between the dmCpGs obtained in each of the analyses and the GO ontol‑
ogy database by the R/Bioconductor package missMethyl. Ontologies 
for genes with 1) both hyper‑ and hypomethylated probes 2) exclusively 
either hyper‑ or hypomethyated and 3) from mapped hyper‑ or hypo‑
methylated dmCpGs which did not take into account CpGs differentially 
methylated in the opposite direction in the same genes are included. 
Also included are the ontologies found when analyzing 0→5 dmCpGs 
grouped by gene region (promoter, exon, intron and gene body). All 
of the analyses include “molecular function”, “cellular component” and 
“biological process” terms.
Additional file 5: Figure S1. Boxplots indicating the distribution of abso‑
lute beta values of the DNA methylation changes for 0→5 and 5→10 
hyper‑ and hypomethylated dmCpGs. Effect size is measured as median 
difference and Cliff’s delta.
Additional file 6: Table S2. Blood cell‑type compositions as predicted by 
the Houseman algorithm for the 33 samples.
Additional file 7: Table S3. Histone mark enrichment analysis of 0→5 
and 5→10 dmCpGs. Enrichments were calculated based on differences 
between the dmCpGs obtained in each of the analyses and the full col‑
lection of Roadmap epigenomics hg19 regions integrated in the LOLA 
extended software. Corresponding array backgrounds were used for the 
different comparisons.
Additional file 8: Table S4. Chromatin state enrichment analysis of 0→5 
and 5→10 dmCpGs. Enrichments were calculated based on differences 
between the dmCpGs obtained in each of the analyses and the hg19 
chromatin segmentation regions (ChromHMM, 18 states) obtained from 
Roadmap and ENCODE consortia. A custom LOLA database including 
information related to the chromatin states in the different tissues/cell 
lines and corresponding array backgrounds were used for the correct 
enrichment calculation.
Additional file 9: Table S5. Enhancer element enrichment analysis of 
0→5 and 5→10 dmCpGs. Enrichments were calculated from the dif‑
ference between the dmCpGs obtained in each of the analyses and the 
enhancer elements obtained from the EnhancerAtlas database. A custom‑
ized LOLA database which included information related to the enhancers 
in the different tissues/cell lines and corresponding array backgrounds 
were used for the appropriate enrichment calculation.
Additional file 10: Figure S2. a) Treemap plots indicating the results of 
REViGO sematic analyses of significantly enriched (FDR < 0.05) gene ontol‑
ogy biological process terms for genes that simultaneously contained 
0→5 hyper‑ and hypomethylated dmCpGs. In total, 460 significant terms 
were found (see Table S6 for full results, including Molecular Function 
and Cellular Component terms, and also 5→10 dmCpG enrichments). b) 
Equivalent plots for genes containing, respectively, hyper‑ or hypomethyl‑
ated dmCpGs, irrespective of those same genes also containing dmCpGs 
that changed in the opposite direction.
Additional file 11: Figure S3. Treemap plots indicating the results of 
REViGO sematic analyses of significantly enriched (FDR < 0.05) gene 
ontology biological process terms for genes containing (a) hyper‑ and (b) 
hypomethylated 0→5 dmCpGs. The dmCpGs are grouped by annotated 
genomic location (see Table S1, column “annotation”, for the annotations; 
“promoter” is formed by collapsing “Distal promoter” and “Promoter (<= 
1kb)”, “gene body” is formed by collapsing “3’ UTR”, “5’ UTR”, “Intron”, “Exon” 
and “Downstream”). See Table S6 for full results, including Molecular Func‑
tion and Cellular Component terms.
Additional file 12: Figure S4. Boxplots showing the DNA methylation 
beta values of the 36 common 0→5→10 dmCpGs described in Table 2.
Additional file 13: Table S7. DNA methylation values obtained by 
bisulfite sequencing for 3 CpGs across the original 33 subjects (techni‑
cal validation) and two independent longitudinal cohorts (biological 
validation).
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